SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-074005
Filing Date
2022-03-14
Accepted
2022-03-14 06:49:04
Documents
13
Period of Report
2022-03-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d317413d8k.htm   iXBRL 8-K 23604
2 EX-99.1 d317413dex991.htm EX-99.1 71680
  Complete submission text file 0001193125-22-074005.txt   230953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA verv-20220314.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20220314_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20220314_pre.xml EX-101.PRE 11708
7 EXTRACTED XBRL INSTANCE DOCUMENT d317413d8k_htm.xml XML 3473
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 22735031
SIC: 2834 Pharmaceutical Preparations